‘No’ vote on broader labels for prostate drugs (Morning Read)

Would the Food and Drug Administration advisory committee recommend that the labels of two drugs -- dutasteride, made by GlaxoSmithKline and sold as Avodart; and finasteride, a generic made by Merck and sold as Proscar -- be changed to say they can reduce a man's risk of getting prostate cancer? The answer was no, reports the New York Times.